Psoriatic arthritis (PsA) is a complex autoimmune disease with genetic and immunological components influencing its pathogenesis. HLA antigens are critical in determining genetic predisposition and clinical variability. This study aims to explore HLA antigen diversity in PsA patients and its relationship to clinical variants.
Cardiovascular comorbidities in psoriatic arthritis - study of patients from the Republic of Moldova
Psoriatic arthritis (PsA) is a chronic musculoskeletal and cutaneous inflammatory disease that affects about 20-30% of patients with psoriasis. In addition to musculoskeletal and cutaneous manifestations, patients with PsA have a higher prevalence of comorbidities compared to the general population. More than half of patients with PsA have at least one comorbidity, with up to 40% of patients having more than three comorbidities.
Study of clinical manifestations in psoriatic arthritis: enthesitis, dactylitis, peripheral arthritis, axial arthritis, skin manifestations, for early diagnosis, which would allow the establishment of an adjusted treatment and the elaboration of measures to prevent complications.
Psoriatic arthritis (PsA) is a chronic musculoskeletal and cutaneous inflammatory disease that affects about 20-30% of patients with psoriasis. In addition to musculoskeletal and cutaneous manifestations, patients with PsA have a higher prevalence of comorbidities compared to the general population. More than half of patients with PsA have at least one comorbidity, with up to 40% of patients having more than three comorbidities. PsA has a particularly strong association with metabolic diseases and, as a result, with cardiovascular diseases (CVD).
Improvement of early diagnosis of psoriatic arthritis based on clinical data, immunological and mathematical research methods.
Psoriatic arthritis (PsA) is one of the most important diseases of great medical and social importance, due to its progressive and significant takeover, which can lead to early disability. The prevalence of psoriatic arthritis is evidenced in the age range of 20-50 years, and both sexes are equally affected. PsA usually has a violent progression with osteo-articular mutilation.